DE602004023183D1 - Gegen antikörper gerichtete photodynamische therapie - Google Patents

Gegen antikörper gerichtete photodynamische therapie

Info

Publication number
DE602004023183D1
DE602004023183D1 DE602004023183T DE602004023183T DE602004023183D1 DE 602004023183 D1 DE602004023183 D1 DE 602004023183D1 DE 602004023183 T DE602004023183 T DE 602004023183T DE 602004023183 T DE602004023183 T DE 602004023183T DE 602004023183 D1 DE602004023183 D1 DE 602004023183D1
Authority
DE
Germany
Prior art keywords
photodynamic therapy
provided against
therapy provided
against antibodies
photosensitizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004023183T
Other languages
English (en)
Inventor
Randolph D Glickman
George L Mayo
Stuart J Mckinnon
Robert F Melendez
Neeru C Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE602004023183D1 publication Critical patent/DE602004023183D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE602004023183T 2003-03-07 2004-03-08 Gegen antikörper gerichtete photodynamische therapie Expired - Lifetime DE602004023183D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45265503P 2003-03-07 2003-03-07
PCT/US2004/006985 WO2004080284A2 (en) 2003-03-07 2004-03-08 Antibody-targeted photodynamic therapy

Publications (1)

Publication Number Publication Date
DE602004023183D1 true DE602004023183D1 (de) 2009-10-29

Family

ID=32990667

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023183T Expired - Lifetime DE602004023183D1 (de) 2003-03-07 2004-03-08 Gegen antikörper gerichtete photodynamische therapie

Country Status (6)

Country Link
US (1) US20060231107A1 (de)
EP (1) EP1605847B1 (de)
AT (1) ATE442861T1 (de)
CA (1) CA2530166A1 (de)
DE (1) DE602004023183D1 (de)
WO (1) WO2004080284A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117987A1 (en) * 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
US7465312B2 (en) * 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US8034091B2 (en) 2007-06-08 2011-10-11 Laserix Sarl Method for the ablation of cartilage tissue in a knee joint using indocyanine
US9226917B2 (en) 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
JP5808107B2 (ja) * 2008-12-17 2015-11-10 学校法人慶應義塾 細胞特異的能動集積性を有する光線力学療法剤
WO2011094758A2 (en) * 2010-02-01 2011-08-04 Montefiore Medical Center Methods and devices for crosslinking of corneal collagen and for treatment of disorders of the eye
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
RU2582964C2 (ru) * 2010-07-19 2016-04-27 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака поджелудочной железы
US20130304019A1 (en) * 2010-09-16 2013-11-14 Case Western Reserve University Photodynamic therapy system, device and associated method of treatment
CN103739710B (zh) * 2014-01-26 2015-12-09 中国人民解放军军事医学科学院基础医学研究所 一种抗vegf抗体及其应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2743458T5 (es) 2014-08-08 2023-06-08 Us Health Eliminación fotocontrolada de dianas in vitro e in vivo
EP3331909A1 (de) 2015-08-07 2018-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nahinfrarot-photoimmunotherapie (nir-pit) von suppressorzellen zur behandlung von krebs
CN108136039A (zh) 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 用于光免疫疗法的组合物、联用及相关方法
CN114681623A (zh) 2015-08-18 2022-07-01 乐天医药生技股份有限公司 酞菁染料偶联物的制造方法及稳定偶联物
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4506680A (en) * 1983-03-17 1985-03-26 Medtronic, Inc. Drug dispensing body implantable lead
US4577642A (en) * 1985-02-27 1986-03-25 Medtronic, Inc. Drug dispensing body implantable lead employing molecular sieves and methods of fabrication
US4606118A (en) * 1985-02-27 1986-08-19 Medtronic, Inc. Method of making a drug dispensing body
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5093349A (en) * 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5177073A (en) * 1988-09-30 1993-01-05 Baylor Research Institute Therapeutic compositions derived from photoactive compounds
US5238940A (en) * 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5405957A (en) * 1992-10-30 1995-04-11 The University Of British Columbia Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use
US5454794A (en) * 1993-10-15 1995-10-03 Pdt Systems, Inc. Steerable light diffusing catheter
US5707986A (en) * 1994-03-14 1998-01-13 Miller; Joan W. Angiographic method using green porphyrins in primate eyes
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
EP0820305A2 (de) * 1995-04-04 1998-01-28 Wound Healing of Oklahoma Krebsbehandlung durch photodynamische therapie, zusammen mit einem immunoadjuvans
RU2066552C1 (ru) * 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
WO1997035617A1 (en) * 1996-03-26 1997-10-02 Pharmacyclics, Inc. Use of a texaphyrin in photodynamic therapy of pigment-related lesions
US6416960B1 (en) * 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US5877263A (en) * 1996-11-25 1999-03-02 Meadox Medicals, Inc. Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6364907B1 (en) * 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
EP1133319B1 (de) * 1998-10-16 2006-08-09 The General Hospital Corporation Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
US6344050B1 (en) * 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
EP1185559A2 (de) * 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
EP1267935A2 (de) * 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
US6180087B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US7125542B2 (en) * 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
WO2002007819A1 (en) * 2000-07-24 2002-01-31 Research Development Foundation Enhancement of photodynamic therapy by anti-angiogenic treatment
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
AU2002236988A1 (en) * 2001-02-06 2002-08-19 Novartis Ag Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
AU2002348477A1 (en) 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
OA12720A (en) * 2001-11-09 2006-06-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases.
US6968234B2 (en) * 2002-04-25 2005-11-22 Medtronic, Inc. Implantable medical device having biologically active polymeric casing

Also Published As

Publication number Publication date
WO2004080284A2 (en) 2004-09-23
US20060231107A1 (en) 2006-10-19
WO2004080284A9 (en) 2005-07-28
EP1605847A2 (de) 2005-12-21
EP1605847B1 (de) 2009-09-16
CA2530166A1 (en) 2004-09-23
WO2004080284A3 (en) 2004-10-21
ATE442861T1 (de) 2009-10-15
EP1605847A4 (de) 2008-02-27

Similar Documents

Publication Publication Date Title
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
DK1742644T3 (da) Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
ATE461217T1 (de) Glp-1-verbindungen
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
EP1758595A4 (de) Verwendung von lipidkonjugaten bei der behandlung von erkrankungen
TW200612918A (en) Lonidamine analogs
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
DK1558616T3 (da) Meso-substituerede porphyriner
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
DK1827500T3 (da) Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
BR0010702A (pt) Novas quinonas como terapias de doenças
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
DK1276501T5 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
FI20021617A (fi) Diagnostisia ja terapeuttisia menetelmiä
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HEYER, V., DIPL.-PHYS. DR.RER.NAT., PAT.-ANW., 806